Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ORL007
MIFTS: 53

Oral Cavity Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Oral Cavity Cancer

About this section

MalaCards integrated aliases for Oral Cavity Cancer:

Name: Oral Cavity Cancer 12 15 17
Malignant Neoplasm of Floor of Mouth 12 32
Malignant Neoplasm of Mouth 71
Oral Cavity Carcinoma 71

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases Oral diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:8618
ICD9CM 34 144 144.0 144.1
NCIt 49 C9318
UMLS 71 C0151546 C0153368 C0153369 more
Sources

Summaries for Oral Cavity Cancer

About this section
Disease Ontology : 12 A gastrointestinal system cancer that is located in the oral cavity.

MalaCards based summary : Oral Cavity Cancer, also known as malignant neoplasm of floor of mouth, is related to salivary gland carcinoma and oral cancer. An important gene associated with Oral Cavity Cancer is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Nicotine and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include the, lymph node and tongue, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Sources

Related Diseases for Oral Cavity Cancer

About this section

Diseases in the Oral Cavity Cancer family:

Oral Cavity Carcinoma in Situ

Diseases related to Oral Cavity Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 196)
# Related Disease Score Top Affiliating Genes
1 salivary gland carcinoma 33.0 SOX2 GSTM1 ERBB2 EGFR
2 oral cancer 32.2 GSTM1 EGFR CYP1A1 BAX
3 squamous cell carcinoma 31.7 VEGFA TNFRSF10B ERBB2 EGFR CYP1A1
4 oropharynx cancer 31.7 ERBB2 EGFR CASP8
5 periodontitis 30.7 VEGFA TLR2 IL4 IL18
6 esophageal cancer 30.7 VEGFA SOX2 IL4 GSTM1 ERCC1 ERBB2
7 nasopharyngeal carcinoma 30.6 VEGFA SOX2 GSTM1 ERCC1 ERBB2 EGFR
8 squamous cell carcinoma, head and neck 30.6 VEGFA TNFRSF10B SOX2 MCL1 GSTM1 ERBB2
9 basal cell carcinoma 30.6 VEGFA SOX2 MCL1 GSTM1 ERCC1 EGFR
10 endocarditis 30.5 TLR6 TLR2 CAT
11 lip and oral cavity cancer 12.6
12 oral squamous cell carcinoma 11.6
13 lung non-squamous non-small cell carcinoma 10.8 VEGFA ERBB2 EGFR
14 gastroesophageal junction adenocarcinoma 10.8 VEGFA ERBB2 EGFR
15 submandibular gland cancer 10.8 ERBB2 EGFR CAT
16 placental site trophoblastic tumor 10.8 VEGFA ERBB2 EGFR
17 toxic oil syndrome 10.8 IL4 GSTM1 CYP1A1
18 indolent b-cell non-hodgkin lymphoma 10.8 MCL1 BAX
19 primary peritoneal carcinoma 10.8 VEGFA ERCC1 ERBB2 EGFR
20 recurrent respiratory papillomatosis 10.8 ERBB2 EGFR
21 breast scirrhous carcinoma 10.8 ERBB2 EGFR
22 gastroesophageal adenocarcinoma 10.7 GSTM1 ERCC1 ERBB2 EGFR
23 childhood medulloblastoma 10.7 ERBB2 EGFR CASP8
24 exanthem 10.7 VEGFA ERBB2 EGFR
25 hair disease 10.7 VEGFA IL4 ERBB2 EGFR
26 neurofibromatosis, type ii 10.7 VEGFA TLR2 ERBB2 EGFR
27 estrogen-receptor negative breast cancer 10.7 VEGFA ERBB2 EGFR
28 autonomic nervous system neoplasm 10.7 VEGFA ERBB2 EGFR CASP8
29 peripheral nervous system neoplasm 10.7 VEGFA ERBB2 EGFR CASP8
30 ovary adenocarcinoma 10.7 VEGFA ERBB2 EGFR BAX
31 pancreatic ductal carcinoma 10.7 VEGFA ERBB2 EGFR
32 esophagitis 10.7 VEGFA SOD2 IL4 EGFR
33 central nervous system cancer 10.7 VEGFA SOX2 ERBB2 EGFR
34 mucinous adenocarcinoma 10.7 VEGFA ERBB2 EGFR
35 mycoplasma pneumoniae pneumonia 10.7 TLR2 IL4 IL18 CYP1A1
36 suppression of tumorigenicity 12 10.7 VEGFA SOX2 ERBB2 EGFR CASP8
37 molluscum contagiosum 10.7 TLR2 FADD CASP8
38 ovarian serous cystadenocarcinoma 10.7 VEGFA ERBB2 EGFR BAX
39 bacteriuria 10.7 TLR2 IL18 CAT
40 retinal ischemia 10.7 VEGFA CAT BAX
41 leukocyte disease 10.7 VEGFA MCL1 IL4 ERBB2 EGFR
42 rosacea 10.7 VEGFA TLR2 IL18 GSTM1
43 gliosarcoma 10.7 VEGFA SOX2 IL4 ERBB2 EGFR
44 genital herpes 10.7 TLR2 IL4 IL18
45 pneumoconiosis 10.7 IL4 GSTM1 CAT CASP8
46 asbestosis 10.7 SOD2 GSTM1 CAT
47 malignant glioma 10.7 VEGFA TNFRSF10B EGFR CASP8
48 herpangina 10.7 TLR6 TLR2 IL4
49 female breast cancer 10.7 ERBB2 EGFR CYP1A1
50 barrett esophagus 10.7 SOD2 ERBB2 EGFR CYP1A1

Comorbidity relations with Oral Cavity Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Oral Cavity Cancer:



Diseases related to Oral Cavity Cancer
Sources

Symptoms & Phenotypes for Oral Cavity Cancer

About this section

GenomeRNAi Phenotypes related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 FADD IL18 MCL1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 BAX ERCC1 FADD IL18 MCL1
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.4 BAX CASP8 ERCC1 MCL1

MGI Mouse Phenotypes related to Oral Cavity Cancer:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.47 BAX CASP8 CAT EDNRB EGFR ERBB2
2 growth/size/body region MP:0005378 10.43 BAX CASP8 CYP1A1 EDNRB EGFR ERBB2
3 homeostasis/metabolism MP:0005376 10.43 BAX CASP8 CAT CYP1A1 EDNRB EGFR
4 hematopoietic system MP:0005397 10.41 BAX CASP8 CYP1A1 EDNRB EGFR ERCC1
5 immune system MP:0005387 10.39 BAX CASP8 CYP1A1 EDNRB EGFR ERCC1
6 mortality/aging MP:0010768 10.39 BAX CASP8 CAT CYP1A1 EDNRB EGFR
7 endocrine/exocrine gland MP:0005379 10.38 BAX CASP8 CYP1A1 EDNRB EGFR ERBB2
8 cardiovascular system MP:0005385 10.3 CASP8 EDNRB EGFR ERBB2 FADD GDF15
9 integument MP:0010771 10.27 CASP8 EDNRB EGFR ERBB2 ERCC1 IL18
10 digestive/alimentary MP:0005381 10.24 EDNRB EGFR ERBB2 FADD IL18 IL4
11 embryo MP:0005380 10.23 CASP8 EDNRB EGFR ERBB2 ERCC1 FADD
12 muscle MP:0005369 10.21 BAX CASP8 EDNRB EGFR ERBB2 ERCC1
13 nervous system MP:0003631 10.21 BAX CASP8 EDNRB EGFR ERBB2 ERCC1
14 liver/biliary system MP:0005370 10.18 CASP8 CYP1A1 EGFR ERCC1 FADD GDF15
15 neoplasm MP:0002006 10.14 BAX CASP8 CAT EDNRB EGFR ERBB2
16 hearing/vestibular/ear MP:0005377 10.02 BAX EDNRB EGFR ERCC1 SOD2 SOX2
17 renal/urinary system MP:0005367 10.02 BAX CASP8 EDNRB EGFR ERCC1 GDF15
18 reproductive system MP:0005389 10 BAX EGFR ERBB2 ERCC1 FADD IL4
19 respiratory system MP:0005388 9.81 BAX CASP8 EDNRB EGFR ERBB2 IL4
20 skeleton MP:0005390 9.65 BAX EDNRB EGFR ERBB2 ERCC1 FADD
21 vision/eye MP:0005391 9.28 BAX EDNRB EGFR ERCC1 IL18 IL4
Sources

Drugs & Therapeutics for Oral Cavity Cancer

About this section

Drugs for Oral Cavity Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 116)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
4 Psychotropic Drugs Phase 4
5 Neurotransmitter Agents Phase 4
6 Liver Extracts Phase 4
7 Central Nervous System Stimulants Phase 4
8 Cholinergic Agents Phase 4
9 Nicotinic Agonists Phase 4
10 Cytochrome P-450 Enzyme Inhibitors Phase 4
11 Dopamine Agents Phase 4
12 Antidepressive Agents Phase 4
13
Pilocarpine Approved, Investigational Phase 2, Phase 3 54-71-7, 92-13-7 5910
14
Celecoxib Approved, Investigational Phase 2, Phase 3 169590-42-5 2662
15
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
16
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
17 Muscarinic Agonists Phase 2, Phase 3
18 Gastrointestinal Agents Phase 2, Phase 3
19 Analgesics, Non-Narcotic Phase 2, Phase 3
20 Cyclooxygenase Inhibitors Phase 2, Phase 3
21 Analgesics Phase 2, Phase 3
22 Anti-Inflammatory Agents Phase 2, Phase 3
23 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
24 Angiogenesis Inhibitors Phase 2, Phase 3
25 Hormones Phase 2, Phase 3
26 Antineoplastic Agents, Hormonal Phase 2, Phase 3
27 Cyclooxygenase 2 Inhibitors Phase 2, Phase 3
28 Anti-Infective Agents Phase 2, Phase 3
29 Antiemetics Phase 2, Phase 3
30 Hormone Antagonists Phase 2, Phase 3
31 Anti-Bacterial Agents Phase 2, Phase 3
32 glucocorticoids Phase 2, Phase 3
33
Omeprazole Approved, Investigational, Vet_approved Phase 2 73590-58-6 4594
34
Indomethacin Approved, Investigational Phase 2 53-86-1 3715
35
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
36
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
37
Indinavir Approved Phase 2 150378-17-9 5362440
38
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
39
Zinc Approved, Investigational Phase 2 7440-66-6 32051
40
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
41
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
42
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
43
Hydroxyurea Approved Phase 2 127-07-1 3657
44
Zinc oxide Approved Phase 2 1314-13-2
45
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
46
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
47
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
48
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
49
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
50
Pembrolizumab Approved Phase 2 1374853-91-4

Interventional clinical trials:

(show top 50) (show all 107)
# Name Status NCT ID Phase Drugs
1 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
2 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
3 A Multinational, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancy Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
4 A Phase III Study to Test the Efficacy and Safety of GM-CSF to Reduce the Severity and Duration of Mucosal Injury and Pain (Mucositis) Associated With Curative Radiation Therapy in Head and Neck Cancer Patients Completed NCT00008398 Phase 3
5 Phase III Placebo-Controlled Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma Patients Completed NCT00201279 Phase 3 13-cis Retino Acid
6 Phase III Study Of Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients Completed NCT00201383 Phase 3 cisplatin
7 A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
8 Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer Not yet recruiting NCT04333537 Phase 2, Phase 3 Imaging Agent
9 Multicentre，A Phase II/III Randomized Study of Adjuvant Anti-Angiogenesis Therapy for Patients of High-Risk Oral Cavity Cancer Terminated NCT00934739 Phase 2, Phase 3 Thalidomide, Celebrex;Cyclophosphamide, Dexamethasone
10 Randomized Phase III Trial on Postoperative Chemoradiation in Combination With Anti EGFR-Antibody Versus Postoperative Chemoradiation in Head and Neck Squamous Cell Carcinomas (HNSCC) With High Risk of Locoregional Recurrence Withdrawn NCT01142414 Phase 3 cisplatin;fluorouracil
11 A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy With the IRX 2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity Unknown status NCT02609386 Phase 2 Cyclophosphamide;Indomethacin;Omeprazole
12 Phrase II Single Arm Study of Effect of FDG-PET/CT for Simulation and Radiation Treatment Planning in Oral Unknown status NCT03008694 Phase 2
13 A Phase II Trial of Paclitaxel (TAXOL) Administered as a Weekly One Hour Infusion in Previously Treated Patients With Advanced Head and Neck Cancer Unknown status NCT00003327 Phase 2 paclitaxel
14 A Pilot Study of Amifostine and Concomitant Cisplatin, Paclitaxel and Radiotherapy in Previously Irradiated, Recurrent Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
15 A Phase I/II Study Using Cisplatin and Gemcitabine (Gemzar) for Advanced Head and Neck Cancer (Squamous Cell Carcinoma) Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
16 CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment Followed by 6 Weeks of Cetuximab+RT Post Surgery in Locally Advanced Squamous Cell Carcinoma of the Tongue ; A NEW PARADIGM OF TREATMENT Unknown status NCT01760811 Phase 1, Phase 2 Erbitux,merck serono
17 Health and Economic Outcomes of Two Different Follow up Strategies in Effectively Cured Advanced Head and Neck Cancer Unknown status NCT02262221 Phase 2
18 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
19 A Preoperative Window of Opportunity Study to Assess the Modulation of Biomarkers in the Primary Tumor Site of Patients With Resectable Oral Cavity Cancer (OCC) Randomized to Receive Preoperative Treatment With PF-00299804 Completed NCT01116843 Phase 1, Phase 2 PF-00299804
20 Pilot Study for the Diagnosis of Head and Neck Cancer: Photofrin and Visible Light Completed NCT00002964 Phase 2 porfimer sodium
21 Efficacy of Implant-Supported Maxillofacial Prostheses Completed NCT00006341 Phase 2
22 A Pilot Study of Combined Modality Therapy for Recurrent Head and Neck Carcinoma Completed NCT00003777 Phase 2 amifostine trihydrate;cisplatin;fluorouracil
23 Phase II Study of Preoperative TPF Chemotherapy in Locally Advanced Resectable Oral Cavity Squamous Cell Cancer in Order to Improve the Rate of Pathological Complete Response Completed NCT01914900 Phase 2 docetaxel, cisplatin, 5 fluorouracil
24 Hyperfractionated Radiotherapy With Concomitant Fluorouracil and Hydroxurea for Intermediate Stage Cancer of the Head and Neck Completed NCT00002951 Phase 2 fluorouracil;hydroxyurea
25 Phase II Double-Blind, Placebo Controlled, Randomized Study Of Celecoxib, A Selective COX-2 Inhibitor, In Oral Premalignant Lesions Completed NCT00014404 Phase 2 celecoxib
26 Efficacy Evaluation of the Combination of Valproic Acid and Standard Platinum-based Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Completed NCT01695122 Phase 2 Valproic Acid
27 A Phase 2, Open-label, Proof-of-concept Study to Assess the Ability to Detect Tumours and Angiogenesis Via the Expression of ανβ3/5 Integrin Receptors by [18F]AH-111585 PET Imaging Completed NCT00565721 Phase 2 Fluciclatide Injection - (AH111585 (F18))
28 Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers? Completed NCT00376987 Phase 2
29 A Phase IIb Cancer Prevention Trial of Celecoxib, a Selective COX-2 Inhibitor, in Oral Leukoplakia Completed NCT00101335 Phase 2 celecoxib
30 A Randomized, Double Blind, Placebo-Controlled Phase II Clinical Trial of N(4-Hydroxy-phenyl)Retinamide (Fenretinide, 4HPR) in Oral Leukoplakia Completed NCT00004161 Phase 2 fenretinide;Placebo
31 Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study Completed NCT00052611 Phase 2 Celecoxib
32 Physiotherapy Versus no Physiotherapy to Patients Suffering From Head and Neck Cancer Undergoing Radiotherapy Treatment Completed NCT00780312 Phase 2
33 A Phase II Multi-Center Study of Concomitant Cetuximab and Cisplatin With Re-Irradiation Using Intensity-Modulated Radiotherapy in Patients With Recurrent Squamous Cell Carcinoma of the Head-and-Neck Completed NCT00833261 Phase 2 cetuximab;cisplatin;Nab-Paclitaxel
34 Phase II Study of Single-Agent Cetuximab for Treatment of High-Risk Pre-malignant Upper Aerodigestive Lesions Completed NCT00524017 Phase 2
35 Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial Completed NCT00330382 Phase 2 Bowman-Birk inhibitor concentrate
36 Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135] Completed NCT00064103 Phase 1, Phase 2
37 A Phase II Study of the Effects of Extended Pre-Cessation Bupropion for Smoking Cessation Completed NCT00534001 Phase 2 bupropion hydrochloride
38 Phase II Trial of Nivolumab, an Anti-PD-1 Monoclonal Antibody, as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer Recruiting NCT03021993 Phase 2 Nivolumab
39 Patient-reported Outcome After Radiotherapy of Oral Cavity and Sinonasal Cancer Using an Intraoral Stent Recruiting NCT04330781 Phase 2
40 A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Recruiting NCT03422536 Phase 2 Ficlatuzumab
41 A Phase II Study of Maintenance Tegafur-uracil in Patients With Squamous Cell Carcinoma of Oral Cavity With Extracapsular Spreading of Lymph Nodes Recruiting NCT03121313 Phase 2 tegafur-uracil
42 The LATENT Trial: Lytic Activation To Enhance Neoantigen-directed Therapy A Study to Evaluate the Feasibility and Efficacy of the Combined Use of Avelumab With Valproic Acid for the Treatment of Virus-associated Cancer Recruiting NCT03357757 Phase 2 Valproic Acid
43 Phase II Non-Randomised Controlled Trial Of Concomitant Immune Check Point Inhibitor With Radiotherapy And Chemotherapy Or Cetuximab In Advanced Non Metastatic Head And Neck Cancer Recruiting NCT03532737 Phase 2 Pembrolizumab
44 A Randomized Multicenter Phase II Study Using (2-1[Heyloxyethyl]-2-Devinylpyropheophorbide-a) (HPPH) With PDT Versus Standard of Care Surgery for Patients With T1/T2 N0 Squamous Cell Carcinoma of the Oral Cavity Active, not recruiting NCT03090412 Phase 2 HPPH;Photodynamic Therapy
45 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence in HLA-A2+ Patients With High-Risk Squamous Cell Carcinoma of the Oral Cavity Active, not recruiting NCT02873819 Phase 2 GL-0817;Hiltonol;Sargramostim;cyclophosphamide;Placebo
46 Personalized, Randomized, Phase 2 Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias Active, not recruiting NCT02882282 Phase 2
47 Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity Active, not recruiting NCT02919683 Phase 2 Nivolumab;Ipilimumab
48 A Phase II Open-label, Single Arm Study to Evaluate the Efficacy of Sintilimab(IBI 308) to Prevent High-risk Oral Premalignant Lesions Cancerization Not yet recruiting NCT04065737 Phase 2 Sintilimab
49 NICO - CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer Not yet recruiting NCT03721757 Phase 2
50 Open Label Single Arm Phase Ib-II Study of Pre-operative IPH2201 in Patients With Locally Advanced Resectable Squamous Cell Carcinoma of the Oral Cavity Terminated NCT02331875 Phase 1, Phase 2 IPH2201

Search NIH Clinical Center for Oral Cavity Cancer

Sources

Genetic Tests for Oral Cavity Cancer

About this section
Sources

Anatomical Context for Oral Cavity Cancer

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Oral Cavity Cancer:

19
The

MalaCards organs/tissues related to Oral Cavity Cancer:

40
Lymph Node, Tongue, Breast, Lung, Neutrophil, Testes, Prostate
Sources

Publications for Oral Cavity Cancer

About this section

Articles related to Oral Cavity Cancer:

(show top 50) (show all 893)
# Title Authors PMID Year
1
Zero Echo Time-Based PET/MRI Attenuation Correction in Patients With Oral Cavity Cancer: Initial Experience. 61
32453083 2020
2
Application of proximity ligation assays to identify potential plasma biomarkers in oral cavity cancer patients: A case control study. 61
32568177 2020
3
Host Factors Independently Associated With Prognosis in Patients With Oral Cavity Cancer. 61
32525545 2020
4
Oral Cavity Cancer Outcomes in Remote, Betel Nut-Endemic Pacific Islands. 61
32546006 2020
5
A Genome-Wide Association Study Identifies Two Novel Susceptible Regions for Squamous Cell Carcinoma of the Head and Neck. 61
32276964 2020
6
Elective neck dissection in T1/T2 oral squamous cell carcinoma with N0 neck: essential or not? A systematic review and meta-analysis. 61
32100133 2020
7
The Role of Age and Merkel Cell Polyomavirus in Oral Cavity Cancers. 61
32571145 2020
8
Oral cavity cancer incidence rates in Osaka, Japan between 2000 and 2014. 61
32272382 2020
9
Screening for oral cancer: Future prospects, research and policy development for Asia. 61
32315954 2020
10
Distant metastasis from oral cavity-correlation between histopathology results and primary site. 61
32468449 2020
11
Sarcopenia results in poor survival rates in oral cavity cancer patients. 61
31769607 2020
12
The current markers of cancer stem cell in oral cancers. 61
32135187 2020
13
Mouth Self-Examination for Prevention and Control of Oral Cavity Cancer. 61
32538936 2020
14
Wine Consumption and Oral Cavity Cancer: Friend or Foe, Two Faces of Janus. 61
32486484 2020
15
Prognostic significance of smoking and alcohol history in young age oral cavity cancer. 61
32430951 2020
16
Selected CDKN2A and MDM2 polymorphisms in oral cavity cancer. 61
32379408 2020
17
Smokeless tobacco use and risk of oral cavity cancer 61
31655504 2020
18
Not So Fast: Deintensification Therapy for Locally Advanced Oral Cavity Cancer. 61
32171464 2020
19
Radiological approach for the newly incorporated T staging factor, depth of invasion (DOI), of the oral tongue cancer in the 8th edition of American Joint Committee on Cancer (AJCC) staging manual: assessment of the necessity for elective neck dissection. 61
32356237 2020
20
Functional outcomes of the modified submandibular gland transfer procedure. 61
31087663 2020
21
Are Tracheotomies Required for Patients Undergoing Composite Mandibular Resections for Oral Cancer? 61
32353259 2020
22
A Survey of Areca (Betel) Nut Use and Oral Cancer in the Commonwealth of the Northern Mariana Islands. 61
32328582 2020
23
Meta-analysis of the association between dietary inflammatory index (DII) and upper aerodigestive tract cancer risk. 61
32332658 2020
24
The worldwide burden of smoking-related oral cancer deaths. 61
32250564 2020
25
Large Idiopathic Mesenteric Necrotizing Granuloma Mimicking Metastatic Disease on FDG PET/CT. 61
31977494 2020
26
Association between pioglitazone use and head and neck cancer: Population-based case-control study. 61
31833151 2020
27
Tongue function and its influence on masticatory performance in patients treated for oral cancer: a five-year prospective study. 61
31273502 2020
28
Prevalence and incidence of oral cancer in low- and middle-income countries: A scoping review. 61
31820851 2020
29
Attributable fraction for multiple risk factors: Methods, interpretations, and examples. 61
31074326 2020
30
Temporal Trajectory of Body Image Disturbance in Patients with Surgically Treated Head and Neck Cancer. 61
31906788 2020
31
An alternative to skin graft for superficial surgical defect in oral cancer surgery. 61
32247765 2020
32
Prognostic implications of stromal hyaluronic acid protein expression in resected oropharyngeal and oral cavity cancers. 61
31352717 2020
33
Predictors of Survival After Head and Neck Squamous Cell Carcinoma in South America: The InterCHANGE Study. 61
32213095 2020
34
Response to nivolumab combining radiotherapy and nimotuzumab in metastatic oral squamous cell carcinoma patient with strong PD-L1 expression: a case report. 61
32355846 2020
35
An immuno-MALDI mass spectrometry assay for the oral cancer biomarker, matrix metalloproteinase-1, in dried saliva spot samples. 61
31987131 2020
36
Pretreatment peripheral blood leukocytes are independent predictors of survival in oral cavity cancer. 61
31809562 2020
37
Indocyanine green and Firefly® for real-time sentinel lymph node mapping in oral cavity cancer. 61
31983438 2020
38
Radiotherapy Is Associated with an Accelerated Risk of Ischemic Stroke in Oral Cavity Cancer Survivors after Primary Surgery. 61
32155918 2020
39
Indian clinical practice consensus guidelines for the management of oral cavity cancer. 61
32167064 2020
40
"Search less, verify more"-Reviewing salivary biomarkers in oral cancer detection. 61
32027406 2020
41
Improving oral cavity cancer diagnosis and treatment with fluorescence molecular imaging. 61
32072691 2020
42
Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher. 61
31837576 2020
43
Alterations in XRCC1 gene profile in pathogenesis of oral cavity cancer: A population-based study from Kamrup Urban District of Assam, India. 61
30954277 2020
44
Association between hydrochlorothiazide exposure and different incident skin, lip and oral cavity cancers: A series of population-based nested case-control studies. 61
32068906 2020
45
Low skeletal muscle mass is a strong predictive factor for surgical complications and a prognostic factor in oral cancer patients undergoing mandibular reconstruction with a free fibula flap. 61
31881447 2020
46
Chemotherapy in the definitive management of oral cancers: Where do we stand today? 61
32032863 2020
47
Prediction of survival of HPV16-negative, p16-negative oral cavity cancer patients using a 13-gene signature: A multicenter study using FFPE samples. 61
31835136 2020
48
18F-FDG PET/CT versus CT/MR imaging for detection of neck lymph node metastasis in palpably node-negative oral cavity cancer. 61
31606761 2020
49
Geographical and Racial Disparities in Head and Neck Cancer Diagnosis in South-Eastern United States: Using Real-World Electronic Medical Records Data. 61
32219195 2020
50
Locally Advanced Oral Cavity Cancers: What Is The Optimal Care? 61
32339002 2020
Sources

Variations for Oral Cavity Cancer

About this section
Sources

Expression for Oral Cavity Cancer

About this section
Search GEO for disease gene expression data for Oral Cavity Cancer.
Sources

Pathways for Oral Cavity Cancer

About this section

Pathways related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show all 46)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 13.99 VEGFA TLR6 TLR2 SOX2 MCL1 IL4
2
ERK Signaling 63
Show member pathways
 13.74 VEGFA TNFRSF10B SOX2 IL4 IL18 GDF15
3
PEDF Induced Signaling 63
Show member pathways
 13.61 TNFRSF10B SOD2 IL4 IL18 GDF15 ERBB2
4
TGF-Beta Pathway 63
Show member pathways
 13.52 VEGFA TNFRSF10B IL4 IL18 GDF15 ERBB2
5
Cytokine Signaling in Immune system 65
Show member pathways
 13.34 VEGFA SOX2 MCL1 IL4 IL18 ERBB2
6
Akt Signaling 63
Show member pathways
 13.25 TNFRSF10B TLR6 TLR2 IL4 IL18 GDF15
7
PAK Pathway 63
Show member pathways
 13.23 TNFRSF10B IL4 IL18 GDF15 ERBB2 EGFR
8
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.04 TLR6 TLR2 FADD EGFR CASP8 BAX
9
Human cytomegalovirus infection 36
Show member pathways
 12.9 VEGFA TLR2 FADD EGFR CASP8 BAX
10
Measles 36
Show member pathways
 12.76 TNFRSF10B TLR2 IL18 FADD CASP8 BAX
11
PI3K-Akt signaling pathway 36
Show member pathways
 12.75 VEGFA TLR2 MCL1 IL4 FADD ERBB2
12
Apoptosis Modulation and Signaling 1
Show member pathways
 12.69 TNFRSF10B MCL1 FADD CASP8 BAX
13
NF-KappaB Family Pathway 63
Show member pathways
 12.68 TLR6 TLR2 GDF15 FADD EGFR
14
TRAF Pathway 63
Show member pathways
 12.55 TNFRSF10B TLR6 TLR2 FADD CASP8
15
NF-kappaB Signaling 4
12.52 TNFRSF10B TLR6 TLR2 IL4 GDF15
16
Apoptosis Pathway 70
Show member pathways
 12.41 ERBB2 EGFR CASP8 BAX
17
Pathways in cancer 36
12.33 VEGFA IL4 GSTM1 FADD ERBB2 EGFR
18
IL-17 Family Signaling Pathways 64
Show member pathways
 12.31 TLR2 IL4 FADD CASP8
19
Proteoglycans in cancer 36
12.28 VEGFA TLR2 ERBB2 EGFR
20
Pathogenic Escherichia coli infection 36
12.22 TNFRSF10B IL18 FADD CASP8 BAX
21
Necroptosis 36
Show member pathways
 12.18 TNFRSF10B FADD CASP8 BAX
22
Colorectal Cancer Metastasis 63
12.13 VEGFA TLR6 TLR2 EGFR BAX
23
Apoptosis and Autophagy 4
12.11 TNFRSF10B MCL1 GDF15 FADD CASP8 BAX
24
Integrated Breast Cancer Pathway 1
12.08 VEGFA FADD EGFR CASP8 BAX
25
Tuberculosis 36
12.05 TLR6 TLR2 IL18 FADD CASP8 BAX
26
Salmonella infection (KEGG) 36
12.01 TNFRSF10B TLR6 TLR2 IL18 FADD CASP8
27
Direct p53 effectors 1
12 TNFRSF10B MCL1 GDF15 EGFR BAX
28
DNA Damage Response (only ATM dependent) 1
11.95 SOD2 ERBB2 CAT BAX
29
MAPK Pathway 70
Show member pathways
 11.95 TLR6 TLR2 ERBB2 EGFR CASP8
30
Interleukin-4 and 13 signaling 65
11.89 VEGFA SOX2 MCL1 IL4 IL18
31
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors 65
Show member pathways
 11.84 VEGFA ERBB2 EGFR
32
Rheumatoid arthritis 36
11.84 VEGFA TLR2 IL18
33
Th17 Differentiation 64
Show member pathways
 11.83 TLR6 TLR2 IL4
34
Nanomaterial induced apoptosis 1
Show member pathways
 11.77 MCL1 FADD CASP8 BAX
35
Bladder cancer 36 1
11.72 VEGFA ERBB2 EGFR
36
Legionellosis 36
11.59 TLR2 IL18 CASP8
37
Photodynamic therapy-induced AP-1 survival signaling. 1
11.54 MCL1 EGFR BAX
38
Aryl Hydrocarbon Receptor Pathway 1
11.5 EGFR CYP1A1 BAX
39
Aryl Hydrocarbon Receptor 1
11.5 VEGFA EGFR CYP1A1
40
all-trans-Retinoic Acid Mediated Apoptosis 63
11.49 TNFRSF10B FADD CASP8
41
Ceramide signaling pathway 1
11.45 FADD CASP8 BAX
42
Apoptosis and survival_Regulation of Apoptosis by Mitochondrial Proteins 22
Show member pathways
 11.41 MCL1 CASP8 BAX
43
Photodynamic therapy-induced HIF-1 survival signaling 1
11.35 VEGFA MCL1 BAX
44
Oxidative Stress 1
11.26 SOD2 CYP1A1 CAT
45
G-protein signaling_Rap2B regulation pathway 22
10.98 IL4 IL18 GDF15 ERBB2 EGFR BAX
46
Platinum drug resistance 36
10.96 GSTM1 FADD ERCC1 ERBB2 CASP8 BAX
Sources

GO Terms for Oral Cavity Cancer

About this section

Cellular components related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell body GO:0044297 9.54 TLR2 FADD CASP8
2 Bcl-2 family protein complex GO:0097136 9.32 MCL1 BAX
3 death-inducing signaling complex GO:0031264 9.26 FADD CASP8
4 ripoptosome GO:0097342 9.16 FADD CASP8
5 membrane raft GO:0045121 9.1 TLR6 TLR2 FADD EGFR EDNRB CASP8
6 CD95 death-inducing signaling complex GO:0031265 8.96 FADD CASP8

Biological processes related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.23 VEGFA TLR2 SOX2 IL4 IL18 FADD
2 apoptotic process GO:0006915 10.12 TNFRSF10B TLR2 MCL1 FADD CASP8 BAX
3 negative regulation of apoptotic process GO:0043066 10.05 VEGFA MCL1 IL4 EGFR EDNRB CAT
4 positive regulation of cell migration GO:0030335 10 VEGFA SOD2 IL4 EGFR
5 signal transduction GO:0007165 10 VEGFA TNFRSF10B TLR6 TLR2 IL4 IL18
6 positive regulation of gene expression GO:0010628 9.99 VEGFA TLR6 TLR2 IL4 IL18 ERBB2
7 cytokine-mediated signaling pathway GO:0019221 9.97 VEGFA SOX2 MCL1 IL4 IL18
8 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.96 TNFRSF10B TLR6 FADD CASP8
9 positive regulation of protein phosphorylation GO:0001934 9.96 VEGFA ERBB2 EGFR EDNRB
10 positive regulation of protein kinase B signaling GO:0051897 9.94 IL18 GDF15 ERBB2 EGFR
11 response to hypoxia GO:0001666 9.93 VEGFA TLR2 CYP1A1 CAT
12 response to lipopolysaccharide GO:0032496 9.93 TLR2 EDNRB CYP1A1 CASP8
13 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.92 TLR6 TLR2 IL18 CAT
14 regulation of apoptotic process GO:0042981 9.92 TNFRSF10B MCL1 FADD CASP8 BAX
15 cell proliferation GO:0008283 9.91 IL18 ERCC1 CYP1A1 BAX
16 positive regulation of inflammatory response GO:0050729 9.89 TLR2 IL18 EGFR
17 response to wounding GO:0009611 9.87 SOX2 CYP1A1 BAX
18 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.87 VEGFA IL4 IL18
19 cellular response to growth factor stimulus GO:0071363 9.87 ERBB2 EGFR CAT
20 cellular response to organic cyclic compound GO:0071407 9.87 IL18 CYP1A1 CASP8
21 apoptotic signaling pathway GO:0097190 9.86 FADD CASP8 BAX
22 kidney development GO:0001822 9.86 VEGFA FADD CAT BAX
23 positive regulation of epithelial cell proliferation GO:0050679 9.85 VEGFA ERBB2 EGFR
24 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.85 TLR2 IL18 EGFR
25 positive regulation of MAP kinase activity GO:0043406 9.85 VEGFA ERBB2 EGFR
26 cell surface receptor signaling pathway GO:0007166 9.8 TNFRSF10B FADD ERBB2 EGFR EDNRB CASP8
27 extrinsic apoptotic signaling pathway GO:0097191 9.79 FADD CASP8 BAX
28 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.77 TNFRSF10B FADD CASP8
29 response to toxic substance GO:0009636 9.76 TLR2 CYP1A1 CAT BAX
30 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.73 TNFRSF10B FADD CASP8 BAX
31 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.72 TLR6 FADD CASP8
32 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 9.71 SOX2 BAX
33 UV protection GO:0009650 9.71 ERCC1 CAT
34 cell activation GO:0001775 9.71 TLR6 TLR2
35 regulation of cytokine secretion GO:0050707 9.71 TLR6 TLR2
36 microglial cell activation GO:0001774 9.71 TLR6 TLR2 IL4
37 cellular response to mechanical stimulus GO:0071260 9.71 TNFRSF10B FADD EGFR CASP8
38 toll-like receptor 3 signaling pathway GO:0034138 9.7 FADD CASP8
39 death-inducing signaling complex assembly GO:0071550 9.68 FADD CASP8
40 cellular response to bacterial lipopeptide GO:0071221 9.68 TLR6 TLR2
41 regulation of necroptotic process GO:0060544 9.67 FADD CASP8
42 negative regulation of ERBB signaling pathway GO:1901185 9.65 ERBB2 EGFR
43 cellular response to diacyl bacterial lipopeptide GO:0071726 9.65 TLR6 TLR2
44 type 2 immune response GO:0042092 9.65 IL4 IL18
45 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.61 CASP8 BAX
46 toll-like receptor TLR6:TLR2 signaling pathway GO:0038124 9.6 TLR6 TLR2
47 nitric oxide metabolic process GO:0046209 9.58 TLR6 TLR2
48 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.54 TNFRSF10B FADD CASP8
49 detection of diacyl bacterial lipopeptide GO:0042496 9.49 TLR6 TLR2
50 response to bacterial lipoprotein GO:0032493 9.48 TLR6 TLR2

Molecular functions related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.28 VEGFA TNFRSF10B TLR6 TLR2 SOX2 MCL1
2 cytokine activity GO:0005125 9.71 VEGFA IL4 IL18 GDF15
3 protein homodimerization activity GO:0042803 9.63 VEGFA MCL1 GSTM1 GDF15 CAT BAX
4 lipopeptide binding GO:0071723 9.37 TLR6 TLR2
5 identical protein binding GO:0042802 9.32 VEGFA TLR6 TLR2 SOD2 FADD ERBB2
6 BH3 domain binding GO:0051434 9.26 MCL1 BAX
7 death effector domain binding GO:0035877 8.96 FADD CASP8
Sources

Sources for Oral Cavity Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....